Ligand ID: CA4 Drugbank ID: DB04839(Cyproterone acetate) Indication:For the palliative treatment of patients with advanced prostatic carcinoma. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 1q2w | 3C-LIKE PROTEASE (SARSr-CoV) | 5 / 12 | GLN A 127VAL B 125ARG A 298ALA A 116PHE A 140 | 1.40A | 20.99 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 1z1j | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | GLN A 127VAL B1125ARG A 298ALA A 116PHE A 140 | 1.39A | 21.41 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 2a5k | 3C-LIKE PEPTIDASE (SARSr-CoV) | 5 / 12 | GLN A 127VAL B 125ARG A 298ALA A 116PHE A 140 | 1.41A | 21.34 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 2acf | REPLICASEPOLYPROTEIN 1AB (SARS-COVTor2) | 5 / 12 | LEU D 225ASN D 222LEU D 257MET D 243ALA D 232 | 1.39A | 21.29 | None | ||
![]() | 2OZ7_A_CA4A1_2 (ANDROGEN RECEPTOR) | 2ahm | REPLICASEPOLYPROTEIN 1AB,HEAVY CHAINREPLICASEPOLYPROTEIN 1AB,LIGHT CHAIN (SARSr-CoV) | 4 / 6 | LEU C 18TRP C 34MET H 75LEU C 33 | 1.70A | 17.72 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 2d2d | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | GLN B 127VAL A 125ARG B 298ALA B 116PHE B 140 | 1.28A | 21.45 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 2fav | REPLICASEPOLYPROTEIN 1AB(PP1AB) (ORF1AB) (SARSr-CoV) | 5 / 12 | LEU C 44ASN C 41LEU C 76MET C 62ALA C 51 | 1.41A | 22.09 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 2h85 | PUTATIVE ORF1ABPOLYPROTEIN (SARSr-CoV) | 5 / 12 | LEU A 72ASN A 73LEU A 75GLY A 76VAL A 121 | 1.10A | 21.11 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 2op9 | REPLICASEPOLYPROTEIN 1AB(PP1AB, ORF1AB)3C-LIKE PROTEINASE(3CL-PRO, 3CLP) (SARSr-CoV) | 5 / 12 | GLN A 127VAL B 125ARG A 298ALA A 116PHE A 140 | 1.36A | 20.92 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 2ozk | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARSr-CoV) | 5 / 12 | LEU A 72ASN A 73LEU A 75GLY A 76VAL A 121 | 1.12A | 21.33 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 2rhb | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARSr-CoV) | 5 / 12 | LEU C 72ASN C 73LEU C 75GLY C 76VAL C 121 | 1.06A | 21.21 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 2w2g | NSP3 (SARSr) | 5 / 12 | LEU A 596ASN A 597LEU A 599VAL A 604ARG A 579 | 1.46A | 20.00 | NoneSO4 A1653 (-4.4A)NoneNoneNone | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 2w2g | NSP3 (SARSr) | 5 / 12 | LEU B 596ASN B 597LEU B 599VAL B 604ARG B 579 | 1.45A | 20.00 | NoneSO4 B1653 (-4.1A)NoneNoneNone | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 3atw | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | GLN A 127VAL B 125ARG A 298ALA A 116PHE A 140 | 1.41A | 21.67 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 3bgf | SPIKE PROTEIN S1 (SARSr-CoV) | 5 / 12 | LEU A 374ASN A 375LEU A 377VAL A 382ALA A 350 | 1.46A | 19.08 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 3d0h | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 5 / 12 | ASN B 508LEU B 120VAL B 184ALA B 501LEU B 503 | 1.45A | 17.90 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 3scj | ACE2 (Homosapiens) | 5 / 12 | ASN A 508LEU A 120VAL A 184ALA A 501LEU A 503 | 1.40A | 17.16 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 3scl | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 5 / 12 | ASN A 508LEU A 120VAL A 184ALA A 501LEU A 503 | 1.35A | 17.05 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 3snd | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | GLN A 127VAL B 125ARG A 298ALA A 116PHE A 140 | 1.34A | 21.41 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 5b6o | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | GLN B 127VAL A 125ARG B 298ALA B 116PHE B 140 | 1.38A | 21.45 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6acg | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | LEU C 532GLY C 531ARG C 553ALA C 506LEU C 504 | 1.32A | 11.65 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6crv | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 12 | ASN C 528LEU C 532GLY C 531VAL A 958ARG C 553 | 1.46A | 11.63 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6cs2 | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 12 | ASN B 528LEU B 532GLY B 531VAL C 958ARG B 553 | 1.37A | 11.72 | None | ||
![]() | 2OZ7_A_CA4A1_2 (ANDROGEN RECEPTOR) | 6m17 | SODIUM-DEPENDENTNEUTRAL AMINO ACIDTRANSPORTER B(0)AT1 (Homosapiens) | 4 / 6 | LEU A 238TRP A 416MET A 410LEU A 244 | 1.71A | 16.16 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6m18 | SODIUM-DEPENDENTNEUTRAL AMINO ACIDTRANSPORTER B(0)AT1 (Homosapiens) | 5 / 12 | LEU A 43LEU A 46GLY A 47VAL A 232PHE A 433 | 1.37A | 16.16 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU C 227LEU C 262VAL C 202ALA C 234LEU C 232 | 1.56A | 20.24 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 250LEU A 253VAL A 204ALA A 266LEU A 262 | 1.62A | 20.24 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU C 250LEU C 253VAL C 204ALA C 266LEU C 262 | 1.61A | 20.24 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 227LEU A 262VAL A 202ALA A 234LEU A 232 | 1.69A | 20.24 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLN C 127VAL A 125ARG C 298ALA C 116PHE C 140 | 1.56A | 20.24 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU D 250LEU D 253VAL D 204ALA D 266LEU D 262 | 1.65A | 20.24 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLN A 127VAL C 125ARG A 298ALA A 116PHE A 140 | 1.47A | 20.24 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU B 250LEU B 253VAL B 204ALA B 266LEU B 262 | 1.63A | 20.24 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 707LEU A 775GLY A 774GLN A 773ALA A 46 | 1.46A | 14.15 | None | ||
![]() | 2OZ7_A_CA4A1_2 (ANDROGEN RECEPTOR) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 4 / 6 | TRP A 509MET B 87MET B 90LEU A 371 | 1.75A | 14.15 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6vww | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | LEU A 73ASN A 74LEU A 76GLY A 77VAL A 122 | 1.03A | 20.86 | NoneNoneNoneGOL A 404 (-4.4A)None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 127LEU A 126VAL A 35ALA A 39PHE A 132 | 1.54A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 109LEU A 108GLY A 97ALA A 129LEU A 126 | 1.67A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 109LEU B 108GLY B 97ALA B 129LEU B 126 | 1.68A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 109LEU A 108GLY A 78ALA A 38PHE A 116 | 1.58A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 127LEU B 126VAL B 35ALA B 39PHE B 132 | 1.63A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w02 | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 43ASN B 40LEU B 75MET B 61ALA B 50 | 1.40A | 22.57 | NoneAPR B 201 (-3.8A)NoneNoneAPR B 201 (-3.6A) | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w41 | CR3022 FAB LIGHTCHAIN (Homosapiens) | 5 / 12 | LEU L 73VAL L 58ARG L 61ALA L 34LEU L 33 | 1.77A | 20.39 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A7073ASN A7008LEU A7072GLY A7076VAL A7057 | 1.53A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 109LEU B 108GLY B 78ALA B 38PHE B 116 | 1.51A | NoneNoneNoneMES B 201 ( 3.4A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 43ASN A 40VAL A 35MET A 61ALA A 50 | 1.78A | 23.33 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 127LEU A 126VAL A 35ALA A 39PHE A 132 | 1.72A | 23.33 | NoneAMP A 201 ( 4.4A)NoneNoneAMP A 201 ( 4.3A) | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 127LEU B 126VAL B 35ALA B 39PHE B 132 | 1.52A | NoneNoneNoneNoneMES B 201 ( 3.4A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 43ASN B 40LEU B 75VAL B 36MET B 61 | 1.69A | NoneMES B 201 ( 3.9A)NoneNoneNone | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 43ASN B 40VAL B 35MET B 61ALA B 50 | 1.77A | 23.33 | NoneMES B 201 ( 3.9A)NoneNoneMES B 201 ( 3.7A) | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 53GLY A 48VAL A 96ALA A 124LEU A 123 | 1.75A | 23.33 | NoneAMP A 201 ( 3.6A)NoneNoneNone | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 43ASN A 40LEU A 75VAL A 36MET A 61 | 1.74A | 23.33 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 53GLY B 48VAL B 96ALA B 124LEU B 123 | 1.78A | 23.33 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 109LEU A 108GLY A 78ALA A 38PHE A 116 | 1.58A | NoneNoneNoneAMP A 201 ( 3.9A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 43ASN B 40LEU B 75MET B 61ALA B 50 | 1.37A | NoneMES B 201 ( 3.9A)NoneNoneMES B 201 ( 3.7A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 43ASN A 40LEU A 75MET A 61ALA A 50 | 1.39A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 109LEU A 108GLY A 97ALA A 129LEU A 126 | 1.69A | NoneNoneNoneAMP A 201 ( 3.4A)AMP A 201 ( 4.4A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C7073ASN C7008LEU C7072GLY C7076VAL C7057 | 1.56A | 19.69 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C6892ASN A7096VAL A7092ARG C7085ALA C6905 | 1.78A | 19.69 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | ASN C6994GLN C6850VAL C6842ALA C6832LEU C7037 | 1.59A | 19.69 | NoneNoneNoneFMT C7111 ( 3.6A)None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | ASN A6994GLN A6850VAL A6842ALA A6832LEU A7037 | 1.61A | 19.69 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A7073ASN A7008LEU A7072GLY A7076VAL A7057 | 1.56A | 19.69 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 43ASN A 40LEU A 75VAL A 36MET A 61 | 1.69A | NoneMES A 201 (-3.9A)NoneNoneNone | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 127LEU A 126VAL A 35ALA A 39PHE A 132 | 1.49A | NoneNoneNoneMES A 201 ( 4.7A)MES A 201 (-2.5A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 43ASN A 40LEU A 75MET A 61ALA A 50 | 1.37A | NoneMES A 201 (-3.9A)NoneNoneMES A 201 ( 3.0A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 109LEU A 108GLY A 78ALA A 38PHE A 116 | 1.47A | NoneNoneNoneMES A 201 (-3.6A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wen | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 109LEU A 108GLY A 78ALA A 38PHE A 116 | 1.61A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wen | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 109LEU A 108GLY A 97ALA A 129LEU A 126 | 1.57A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wen | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 127LEU A 126VAL A 35ALA A 39PHE A 132 | 1.68A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wey | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 331LEU A 330VAL A 239ALA A 243PHE A 336 | 1.66A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wey | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 357LEU A 216ARG A 345LEU A 327PHE A 210 | 1.59A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wey | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 247ASN A 244LEU A 279MET A 265ALA A 254 | 1.37A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wey | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 313LEU A 312GLY A 282ALA A 242PHE A 320 | 1.64A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU C7073ASN C7008LEU C7072GLY C7076VAL C7057 | 1.55A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU C6892ASN A7096VAL A7092ARG C7085ALA C6905 | 1.61A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ASN C6994GLN C6850VAL C6842ALA C6832LEU C7037 | 1.59A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A7073ASN A7008LEU A7072GLY A7076VAL A7057 | 1.56A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C7073ASN C7008LEU C7072GLY C7076VAL C7057 | 1.56A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A7073ASN A7008LEU A7072GLY A7076VAL A7057 | 1.57A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | ASN C6994GLN C6850VAL C6842ALA C6832LEU C7037 | 1.60A | NoneNoneNoneFMT C7111 ( 3.5A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | LEU A 73ASN A 74LEU A 76GLY A 77VAL A 122 | 1.06A | NoneEDO A 406 (-4.5A)NoneEDO A 406 ( 3.9A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | LEU B 73ASN B 74LEU B 76GLY B 77VAL B 122 | 1.07A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU B 53GLY B 48VAL B 96ALA B 124LEU B 123 | 1.68A | NoneAPR B 201 (-3.4A)NoneNoneNone | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU B 109LEU B 108GLY B 78ALA B 38PHE B 116 | 1.53A | NoneNoneNoneAPR B 201 (-3.3A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU D 127LEU D 126VAL D 35ALA D 39PHE D 132 | 1.58A | NoneNoneNoneNoneAPR D 201 (-3.5A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 127LEU A 126VAL A 35ALA A 39PHE A 132 | 1.51A | NoneNoneNoneNoneAPR A 201 (-3.1A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU C 127LEU C 126VAL C 35ALA C 39PHE C 132 | 1.48A | NoneAPR C 201 (-4.9A)NoneNoneAPR C 201 (-3.5A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU B 127LEU B 126VAL B 35ALA B 39PHE B 132 | 1.53A | NoneNoneNoneNoneAPR B 201 (-3.6A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU B 43ASN B 40LEU B 75MET B 61ALA B 50 | 1.43A | NoneAPR B 201 (-3.6A)NoneNoneAPR B 201 (-3.3A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 109LEU A 108GLY A 78ALA A 38PHE A 116 | 1.54A | NoneNoneNoneAPR A 201 (-3.5A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU D 43ASN D 40LEU D 75MET D 61ALA D 50 | 1.45A | NoneAPR D 201 (-3.6A)NoneNoneAPR D 201 ( 3.7A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU C 43ASN C 40LEU C 75MET C 61ALA C 50 | 1.45A | NoneAPR C 201 (-3.7A)NoneNoneAPR C 201 (-3.5A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU C 109LEU C 108GLY C 78ALA C 38PHE C 116 | 1.56A | NoneNoneNoneAPR C 201 (-3.4A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU D 109LEU D 108GLY D 78ALA D 38PHE D 116 | 1.54A | NoneNoneNoneAPR D 201 (-3.2A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 109LEU A 108GLY A 97ALA A 129LEU A 126 | 1.66A | NoneNoneNoneAPR A 201 (-3.7A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A7073ASN A7008LEU A7072GLY A7076VAL A7057 | 1.52A | None | |||
![]() | 2OZ7_A_CA4A1_2 (ANDROGEN RECEPTOR) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 6 | LEU C 13MET C 3MET B 90LEU C 40 | 1.78A | 15.26 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6y2g | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | GLN B 127VAL A 125ARG B 298ALA B 116PHE B 140 | 1.34A | 20.24 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 250LEU A 253VAL A 204ALA A 266LEU A 262 | 1.66A | 21.26 | None | ||
![]() | 2OZ7_A_CA4A1_2 (ANDROGEN RECEPTOR) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 6 | LEU C 40MET D 90MET D 94LEU D 91 | 1.76A | 16.03 | None | ||
![]() | 2OZ7_A_CA4A1_2 (ANDROGEN RECEPTOR) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 6 | LEU A 40MET B 90MET B 94LEU B 91 | 1.76A | 16.03 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 109LEU E 108GLY E 78ALA E 38PHE E 116 | 1.54A | NoneNoneNoneEPE E 202 (-3.3A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 109LEU A 108GLY A 97ALA A 129LEU A 126 | 1.64A | NoneEDO D 202 ( 4.8A)EDO A 202 ( 4.9A)NoneNone | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 127LEU C 126VAL C 35ALA C 39PHE C 132 | 1.68A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 127LEU E 126VAL E 35ALA E 39PHE E 132 | 1.51A | NoneNoneNoneNoneEPE E 202 (-3.2A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 127LEU A 126VAL A 35ALA A 39PHE A 132 | 1.52A | EDO A 202 ( 4.8A)NoneNoneNoneEDO A 202 (-3.9A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU D 127LEU D 126VAL D 35ALA D 39PHE D 132 | 1.58A | NoneNoneNoneNoneEDO D 205 ( 3.6A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 43ASN C 40LEU C 75MET C 61ALA C 50 | 1.39A | NoneNoneEPE C 202 (-3.4A)NoneNone | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 75GLY A 78GLN D 118ALA A 38PHE A 132 | 1.30A | NoneNoneEDO D 201 ( 4.4A)EDO A 202 (-3.3A)EDO A 202 (-3.9A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 88ASN C 87GLY C 85ALA C 60PHE D 156 | 1.63A | NoneNoneNoneNoneEDO D 209 ( 3.6A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU D 109LEU D 108GLY D 78ALA D 38PHE D 116 | 1.59A | EDO D 204 ( 4.5A)NoneNoneEDO D 205 (-3.5A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 127LEU B 126VAL B 35ALA B 39PHE B 132 | 1.67A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 43ASN B 40LEU B 75MET B 61ALA B 50 | 1.41A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 109LEU B 108GLY B 78ALA B 38PHE B 116 | 1.59A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 109LEU A 108GLY A 78ALA A 38PHE A 116 | 1.54A | NoneEDO D 202 ( 4.8A)NoneEDO A 202 (-3.3A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 109LEU E 108GLY E 97ALA E 129LEU E 126 | 1.64A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 43ASN C 40LEU C 75MET C 61ALA C 50 | 1.42A | NoneAPR C 201 (-3.9A)NoneNoneAPR C 201 (-3.6A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 109LEU C 108GLY C 78ALA C 38PHE C 116 | 1.58A | NoneNoneNoneAPR C 201 (-3.4A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 109LEU A 108GLY A 78ALA A 38PHE A 116 | 1.56A | NoneNoneNoneAPR A 201 (-3.4A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 43ASN E 40LEU E 75MET E 61ALA E 50 | 1.41A | NoneAPR E 201 (-3.9A)NoneNoneAPR E 201 (-3.4A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 127LEU A 126VAL A 35ALA A 39PHE A 132 | 1.53A | NoneAPR A 201 (-4.8A)NoneNoneAPR A 201 (-3.7A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 127LEU B 126VAL B 35ALA B 39PHE B 132 | 1.54A | NoneAPR B 201 (-4.7A)NoneNoneAPR B 201 (-3.5A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 75GLY A 78GLN D 118ALA A 38PHE A 132 | 1.33A | NoneNoneEDO A 207 ( 4.7A)APR A 201 (-3.4A)APR A 201 (-3.7A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 88ASN C 87GLY C 85ALA C 60PHE D 156 | 1.63A | NoneNoneNoneEDO D 204 ( 4.8A)EDO D 204 (-3.9A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU D 127LEU D 126VAL D 35ALA D 39PHE D 132 | 1.54A | NoneAPR D 201 (-4.5A)NoneNoneAPR D 201 (-3.3A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 43ASN B 40LEU B 75MET B 61ALA B 50 | 1.41A | NoneAPR B 201 (-3.8A)NoneNoneAPR B 201 (-3.5A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU D 75GLY D 78GLN A 118ALA D 38PHE D 132 | 1.35A | EDO D 202 (-4.6A)NoneEDO D 203 (-3.7A)APR D 201 (-3.3A)APR D 201 (-3.3A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 127LEU E 126VAL E 35ALA E 39PHE E 132 | 1.48A | NoneAPR E 201 (-4.7A)NoneNoneAPR E 201 (-3.5A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU D 109LEU D 108GLY D 78ALA D 38PHE D 116 | 1.58A | NoneEDO A 206 (-4.6A)NoneAPR D 201 (-3.3A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 127LEU C 126VAL C 35ALA C 39PHE C 132 | 1.53A | NoneAPR C 201 (-4.8A)NoneNoneAPR C 201 (-3.5A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 109LEU B 108GLY B 78ALA B 38PHE B 116 | 1.59A | NoneNoneNoneAPR B 201 (-3.4A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 109LEU C 108GLY C 78ALA C 38PHE C 116 | 1.60A | NoneNoneNoneMES C 201 (-3.5A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 109LEU B 108GLY B 78ALA B 38PHE B 116 | 1.57A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 127LEU C 126VAL C 35ALA C 39PHE C 132 | 1.52A | NoneNoneNoneNoneMES C 201 (-3.6A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU C 75GLY C 78GLN A 118ALA C 38PHE C 132 | 1.32A | NoneNoneEDO A 202 (-4.6A)MES C 201 (-3.5A)MES C 201 (-3.6A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 127LEU A 126VAL A 35ALA A 39PHE A 132 | 1.49A | NoneNoneNoneNoneMES A 201 (-3.5A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU B 127LEU B 126VAL B 35ALA B 39PHE B 132 | 1.55A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 109LEU A 108GLY A 78ALA A 38PHE A 116 | 1.57A | NoneEDO C 205 (-4.9A)NoneMES A 201 (-3.5A)None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU A 75GLY A 78GLN C 118ALA A 38PHE A 132 | 1.28A | NoneNoneEDO A 204 (-4.1A)MES A 201 (-3.5A)MES A 201 (-3.5A) | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 707LEU A 775GLY A 774GLN A 773ALA A 46 | 1.41A | None | |||
![]() | 2OZ7_A_CA4A1_2 (ANDROGEN RECEPTOR) | 7btf | NSP12NSP8 (SARS-CoV-2) | 4 / 6 | TRP A 509MET B 87MET B 90LEU A 371 | 1.71A | 14.15 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | ASN A 703LEU A 708GLN A 724ALA A 771PHE A 753 | 1.58A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 707LEU A 775GLY A 774GLN A 773ALA A 46 | 1.36A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | ASN A 297LEU A 351GLY A 352VAL A 315LEU A 280 | 1.62A | None | |||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | ASN A 297LEU A 351GLY A 352VAL A 315LEU A 280 | 1.55A | None | |||
![]() | 2OZ7_A_CA4A1_2 (ANDROGEN RECEPTOR) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 4 / 6 | TRP A 509MET B 87MET B 90LEU A 371 | 1.74A | 13.66 | None | ||
![]() | 2OZ7_A_CA4A1_1 (ANDROGEN RECEPTOR) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 707LEU A 775GLY A 774GLN A 773ALA A 46 | 1.36A | None |